NCT01838694View on ClinicalTrials.gov

Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE.

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Lupus Erythematosus, Systemic

Interventions

BIOLOGICAL

Ala-Cpn10

DRUG

Placebo

Trial Locations (6)

16635

Altoona Arthritis and Osteoporosis Center, Altoona

33165

Abel Buchheim Pharmaceutical Research, Miami

Unknown

Northwestern University School of Medicine, Chicago

Penn State Milton S. Hershey Medical Center, Hershey

Hospital of the University of Pennsylvania, Philadelphia

Metroplex Clinical Research Center, Dallas

All Listed Sponsors

lead

Invion, Inc.

INDUSTRY

NCT01838694 - Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. | Biotech Hunter | Biotech Hunter